First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Oncology
Reference36 articles.
1. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: a SEER-Medicare historical cohort study in elderly women in the United States: clinical and economic burden of TNBC;Schwartz;Cancer,2018
2. Alarming burden of triple-negative breast cancer in India;Thakur;Clin Breast Cancer,2018
3. An overview of triple-negative breast cancer;Kumar;Arch Gynecol Obstet,2016
4. 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†;Cardoso;Ann Oncol,2018
Cited by 32 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Is bevacizumab a cost‑effective regimen for treating cerebral radiation necrosis in the United States?;Practical Radiation Oncology;2024-08
2. Toripalimab plus chemotherapy in the treatment of metastatic triple-negative breast cancer: a cost-effectiveness analysis;Frontiers in Public Health;2024-07-29
3. Cost-effectiveness of sotorasib as a second-line treatment for non-small cell lung cancer with KRASG12C mutation in China and the United States;Frontiers in Pharmacology;2024-06-14
4. Cost-effectiveness analysis of bevacizumab for cerebral radiation necrosis treatment based on real-world utility value in China;Strahlentherapie und Onkologie;2024-06-03
5. Cost-effectiveness of Sacituzumab Govitecan versus Single-agent Chemotherapy for Patients with Metastatic Triple-Negative Breast Cancer in China;Clinical Breast Cancer;2024-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3